Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
評估福泰製藥：來自11位財務分析師的見解
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 3 | 2 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $495.09, a high estimate of $600.00, and a low estimate of $425.00. Witnessing a positive shift, the current average has risen by 1.47% from the previous average price target of $487.90.
Exploring Analyst Ratings: An In-Depth Overview
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間